Agree Realty stock looks set to outperform with its investment-grade tenants, conservative leverage, and 4.3% yield. Learn more about the trust.

Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management ...

QLi5 Therapeutics GmbH (QLi5), a spin-off from the Max Planck Institute for Biochemistry, has successfully completed a ...

Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose ...

Funding advances Proteasome Inhibitor ADC Platform targeting cancer, inflammatory and autoimmune disordersQLi5 Therapeutics GmbH (QLi5), a spin-off ...

Company expands its ADC pipeline and patent estate for novel, differentiated ADCsNew pipeline candidate AKTX-102 leverages ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. | With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug ...

Through Nov. 15 of last year, pharma deal value rose 79% compared to the same period in 2024, according to Bain. The average deal size also climbed more than 80%, “signaling a decisive return of ...

While investor attention remains fixed on its metabolic blockbusters, pharmaceutical giant Eli Lilly is making significant strategic investments to broaden its therapeutic reach. The company announced ...

Gold soared to a fresh record near $5,600 on Thursday and oil prices climbed after US President Donald Trump ramped up ...

OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...